BrightGene Bio Medical Technology C - Asset Resilience Ratio
BrightGene Bio Medical Technology C (688166) has an Asset Resilience Ratio of 1.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BrightGene Bio Medical Technology C balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how BrightGene Bio Medical Technology C's Asset Resilience Ratio has changed over time. See 688166 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BrightGene Bio Medical Technology C's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688166 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥51.01 Million | 1.0% |
| Total Liquid Assets | CN¥51.01 Million | 1.00% |
Asset Resilience Insights
- Limited Liquidity: BrightGene Bio Medical Technology C maintains only 1.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BrightGene Bio Medical Technology C Industry Peers by Asset Resilience Ratio
Compare BrightGene Bio Medical Technology C's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for BrightGene Bio Medical Technology C (2016–2023)
The table below shows the annual Asset Resilience Ratio data for BrightGene Bio Medical Technology C.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 1.01% | CN¥50.62 Million ≈ $7.41 Million |
CN¥5.03 Billion ≈ $736.32 Million |
-0.07pp |
| 2022-12-31 | 1.08% | CN¥50.12 Million ≈ $7.33 Million |
CN¥4.66 Billion ≈ $682.09 Million |
+1.05pp |
| 2021-12-31 | 0.03% | CN¥763.45K ≈ $111.72K |
CN¥2.97 Billion ≈ $434.55 Million |
-9.82pp |
| 2020-12-31 | 9.85% | CN¥180.04 Million ≈ $26.35 Million |
CN¥1.83 Billion ≈ $267.46 Million |
+9.53pp |
| 2016-12-31 | 0.32% | CN¥1.21 Million ≈ $177.54K |
CN¥384.19 Million ≈ $56.22 Million |
-- |
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more